上海美迪西生物医药股份有限公司 关于 5%以上股东权益变动超过 1%的提示性公告 证券代码：688202 证券简称：美迪西 公告编号：2023-041 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动为上海美迪西生物医药股份有限公司（以下简称"公司"） 2022 年度向特定对象发行 A 股股票（以下简称"本次发行"）导致 5%以上股东持 股比例被动稀释减少，及履行此前披露的股份减持计划，不触及要约收购。 本次权益变动后，公司股东林长青持有公司股份 5,473,654 股，占公司总 股本的 4.07%，股东陈国兴持有公司股份 4,875,154 股，占公司总股本的 3.62%； 二者为一致行动人，合计持有公司股份 10,348,808 股，占公司总股本的比例由 9.02%减少至 7.69%。 本次权益变动不会使公司控股股东、实际控制人发生变化。 一、 本次权益变动的基本情况 1、被动稀释变动情况 公司于 2023 年 2 月 13 日收到中国证监会出具的《关于同意上海美迪西生物 医药股份有限公司向 ...

北京金诚同达律师事务所 关于 上海美迪西生物医药股份有限公司 2022 年度向特定对象发行 A 股股票 发行过程及认购对象合规性的 法律意见书 金证法意 2023 字 0804 第 0607 号 中国北京市建国门外大街1号国贸大厦A座十层 100004 释 义 在本法律意见书中，除非文中另有说明，下列词语具有如下涵义： | 发行人/美迪西/公司 | 指 | 上海美迪西生物医药股份有限公司 | | --- | --- | --- | | 本次发行 | 指 | 美迪西 2022 年度向特定对象发行 A 股股票 | | 《公司法》 | 指 | 《中华人民共和国公司法》 | | 《证券法》 | 指 | 《中华人民共和国证券法》 | | 《注册管理办法》 | 指 | 《上市公司证券发行注册管理办法》 | | 《实施细则》 | 指 | 《上海证券交易所上市公司证券发行与承销业务实施细 则》 | | 《发行方案》 | 指 | 《上海美迪西生物医药股份有限公司 年度向特定对象 2022 | | | | 发行 A 股股票发行方案》 | | 《认购邀请书》 | 指 | 《上海美迪西生物医药股份有限公司向特定对象发行股票 | | ...

截至 2023 年 8 月 4 日止 您可使用手机"扫一扫"或进入"注册会计师行业统一监管半台（http://ac.cod.gov.n）"进行连续 "这"扫"或进入"注册会计师行业统一监管半分（http://ac.co.6.gov.nl）"进行连续 "一" 立信会计师事务所(特殊普通合伙) DO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS I 验 资 报 告 立 ( 上海美迪西生物医药股份有限公司 验资报告 信会师报字[2023]第ZA14977号 上海美迪西生物医药股份有限公司全体股东: 我们接受委托,审验了上海美迪西生物医药股份有限公司(以下 简称"贵公司"或"公司") 截至 2023年8月4日止新增注册资本及实 收资本(股本)情况。按照国家相关法律、法规的规定和协议、章程 的要求出资,提供真实、合法、完整的验资资料,保护资产的安全、 完整是全体股东及贵公司的责任。我们的责任是对贵公司新增注册资 本及实收资本(股本)情况发表审验意见。我们的审验是依据《中国 注册会计师审计准则第 1602 号一验资》进行的。在审验过程中,我 们结合公司的实际情况,实施了检查 ...

上海美迪西生物医药股份有限公司 2022 年度向特定对象发行 A 股股票 发行情况报告书 保荐机构（联席主承销商） 联席主承销商 二〇二三年八月 发行人全体董事、监事及高级管理人员声明 任。 _____________ _____________ _____________ 陈金章 CHUN-LIN CHEN 陈国兴 （陈春麟） _____________ _____________ 赖卫东 马大为 1 本公司全体董事、监事、高级管理人员承诺本发行情况报告书不存在虚假记 载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律责 全体董事签字： _____________ _____________ _____________ 2 本公司全体董事、监事、高级管理人员承诺本发行情况报告书不存在虚假记 _____________ _____________ _____________ 林长青 蔡金娜 许金叶 发行人全体董事、监事及高级管理人员声明 任。 载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律责 全体监事签字： 曾宪成 金伟春 王 磊 3 发行人全体董事、监事及高级管理人员 ...

广发证券股份有限公司 验资报告 司农验字[2023]23006680016 号 目 录 验资报告 …………… ···· 1-2 附件 1 上海美迪西生物医药股份有限公司向特定对象发行股票 投资者认购资金明细表…………………………………………………………………… 3-8 附件 2 上海美迪西生物医药股份有限公司向特定对象发行股票 投资者认购资金流水明细表 …………………………………… 9-16 ┣海美迪西生物医药股份有限公司 向特定对象发行股票 验资报告 司农验字[2023]23006680016号 中国注册会计师:张腾 广发证券股份有限公司: 我们接受委托,审验了广发证券股份有限公司(以下简称"贵公司")作为上海 美迪西生物医药股份有限公司(以下简称"美迪西")向特定对象发行股票之保荐人 (主承销商)截至 2023年 8 月 3 日下午十六时(16:00)止收到投资者认购美迪西本 次向特定对象发行股票资金的情况。按照法律法规的要求提供真实、合法、完整的 验资资料,保护资产的安全、完整是美迪西及贵公司的责任。我们的责任是对截至 2023年 8 月 3 日下午十六时(16:00)止投资者认购美迪西本次向特定对象发 ...

广发证券股份有限公司、中国国际金融股份有限公司 关于上海美迪西生物医药股份有限公司 2022 年度向特定对象发行 A 股股票 发行过程和认购对象合规性的报告 上海证券交易所： 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意上海美迪 西生物医药股份有限公司向特定对象发行股票注册的批复》（证监许可[2023]265 号）批复，同意上海美迪西生物医药股份有限公司（以下简称"美迪西"、"发行 人"或"公司"）向特定对象发行股票的注册申请。 广发证券股份有限公司（以下简称"保荐人（联席主承销商）"或"广发证 券"）作为本次发行的保荐人（联席主承销商），中国国际金融股份有限公司（以 下简称"中金公司"）作为本次发行的联席主承销商（广发证券和中金公司合称 "联席主承销商"），根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《证券发行与承销管理办法》 《上市公司证券发行注册管理办法》（以下简称"《注册管理办法》"）《上海证券 交易所上市公司证券发行与承销业务实施细则》（以下简称"《实施细则》"）等有 关法律、法规、规章制度的要求及美迪西有关本次发行的 ...

上海美迪西生物医药股份有限公司（以下简称"公司"）2022 年度向特定 对象发行 A 股股票（以下简称"本次发行"）发行承销总结相关文件已经上海 证券交易所备案通过，公司将尽快办理本次发行新增股份的登记托管手续。 本 次 发 行 的 具 体 情 况 详 见 公 司 同 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《上海美迪西生物医药股份有限公司 2022 年度向特 定对象发行 A 股股票发行情况报告书》。 证券代码：688202 证券简称：美迪西 公告编号：2023-038 上海美迪西生物医药股份有限公司 关于向特定对象发行A股股票发行情况的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特此公告。 上海美迪西生物医药股份有限公司董事会 2023 年 8 月 11 日 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,658,930,295.46, representing a year-on-year increase of 42.12%[24]. - The net profit attributable to shareholders for 2022 was CNY 338,236,270.93, an increase of 19.85% compared to the previous year[24]. - The net profit after deducting non-recurring gains and losses was CNY 307,111,268.07, reflecting a 13.29% increase year-on-year[24]. - The total assets of the company at the end of 2022 reached CNY 2,329,580,942.76, a growth of 29.89% from the previous year[24]. - The company's net assets attributable to shareholders increased to CNY 1,602,784,731.03, marking a 20.74% rise compared to the end of 2021[24]. - The basic earnings per share for 2022 was CNY 3.89, up 19.69% from CNY 3.25 in 2021[25]. - The company's total share capital as of December 31, 2022, was 87,016,704 shares, with plans for adjustments based on any changes before the dividend distribution date[6]. - The company's management expenses rose by 66.14% to ¥147,957,318.62, driven by increased personnel and operational costs[146]. - The gross profit margin for the clinical research organization (CRO) business was 40.79%, a decrease of 4.52 percentage points year-on-year[150]. Dividend and Capital Plans - The company plans to distribute a cash dividend of 3.90 RMB per 10 shares, totaling approximately 33.94 million RMB, which represents 10.03% of the net profit attributable to shareholders[5]. - The company intends to increase its total share capital from 87,016,704 shares to 121,823,386 shares by converting capital reserves into shares at a ratio of 4 shares for every 10 shares held, resulting in an additional 34,806,682 shares[5]. Audit and Compliance - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy and completeness of the financial report[5]. - The company emphasizes the importance of adhering to regulatory standards, including GLP and AAALAC certifications, to ensure quality in its research and development processes[14]. - The company has a commitment to transparency and has ensured that all board members can guarantee the authenticity of the annual report[9]. - The company has established a research quality control system that meets international standards, achieving GLP certification from China's NMPA and compliance with FDA standards, making it one of the few GLP research institutions that can meet both Chinese and American drug application requirements[128]. Research and Development - The research and development expenditure accounted for 7.41% of operating revenue, an increase of 0.75 percentage points from the previous year[25]. - The company is focusing on developing PROTAC drugs, LYTAC R&D service platform, and enhancing ADC drug discovery capabilities[26]. - The company is advancing the construction of an AI-based preclinical R&D service platform and improving the nucleic acid LNP drug delivery system[26]. - The company has established a comprehensive preclinical research service capability, supporting early screening and IND application processes[43]. - The company has developed advanced technologies in drug discovery, including asymmetric synthesis and computer-aided drug design, enhancing the efficiency of chiral drug development[67]. - The company has established multiple research platforms for active pharmaceutical ingredients (APIs), including green chemistry, polymorph and salt form research, process safety assessment, and quality research platforms[68]. - The company has developed a robust platform for mRNA vaccine non-clinical evaluation, which will support the development and market launch of mRNA products in the future[81]. - The company has established a comprehensive safety production flow for high-activity synthesis, ensuring compliance with OEB4 standards[116]. Market and Competitive Landscape - The global CRO market penetration rate was 46.5% in 2022 and is expected to increase to 55.0% by 2026, indicating a steady growth trend in outsourcing by pharmaceutical companies[60]. - The global CRO market size grew from approximately $49 billion in 2017 to about $71 billion in 2021, with a projected increase to around $118.5 billion by 2026, reflecting a compound annual growth rate (CAGR) of 10.8% from 2021 to 2026[53]. - The Chinese CRO market size increased from approximately 29 billion RMB in 2017 to about 63.9 billion RMB in 2021, with an expected growth to around 187.8 billion RMB by 2026, resulting in a CAGR of 24.1% from 2021 to 2026, which is about twice the global growth rate[54]. - The company faces increased competition from multinational CROs and domestic peers, which may impact its market expansion capabilities[138]. Workforce and Talent Management - The company expanded its workforce to 3,298 employees, a year-on-year increase of 35.16%, with 79.50% holding a bachelor's degree or above[39]. - The number of R&D personnel increased to 2,890, accounting for 87.63% of the total workforce, with an average salary of 15.32 million RMB[125]. - The average salary of R&D personnel increased from 14.67 million RMB to 15.32 million RMB, reflecting the company's investment in talent[125]. - The company faces risks related to rising personnel costs and talent retention, which are critical for maintaining its competitive edge in the CRO industry[134]. - The company is experiencing high talent turnover due to increasing demand for skilled professionals in the CRO sector, which could impact its long-term operations if not managed effectively[135]. Strategic Initiatives and Future Plans - The company is actively pursuing mergers and acquisitions to enhance its product lines and services, increasing industry concentration[186]. - The company aims to expand its international service capabilities and establish overseas laboratories through self-construction or acquisitions[190]. - The company plans to establish a dedicated platform for the discovery of nanobody drugs, which will include a comprehensive nanobody library and high-throughput expression and functional validation[192]. - The company is committed to optimizing its organizational structure and enhancing management capabilities to support its growing business scale[194]. - The company will implement a talent development strategy focusing on collaboration with educational institutions and enhancing training programs for its workforce[194].

Financial Performance - The company's operating revenue for Q1 2023 was ¥451,400,695.33, representing a year-on-year increase of 26.80%[5] - The net profit attributable to shareholders for the same period was ¥101,568,576.29, reflecting a growth of 31.58% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,677,712.67, with a year-on-year increase of 32.06%[5] - Basic earnings per share for Q1 2023 were ¥1.17, up by 31.46% year-on-year[6] - Total revenue for Q1 2023 reached RMB 451.4 million, a 27% increase from RMB 356.0 million in Q1 2022[19] - Operating profit for Q1 2023 was RMB 114.9 million, up 29% from RMB 88.9 million in Q1 2022[20] - Net profit for Q1 2023 was RMB 101.6 million, representing a 31% increase compared to RMB 77.2 million in Q1 2022[20] - Basic and diluted earnings per share for Q1 2023 were both RMB 1.17, compared to RMB 0.89 in Q1 2022[21] Research and Development - The total R&D investment amounted to ¥28,370,481.60, accounting for 6.28% of operating revenue, a decrease of 0.30 percentage points from the previous year[6] - Research and development expenses for Q1 2023 totaled RMB 28.4 million, an increase of 21% from RMB 23.4 million in Q1 2022[19] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,468,249,929.75, an increase of 5.95% from the end of the previous year[6] - The company's current assets totaled RMB 1,178,798,922.61, up from RMB 1,072,633,100.49 at the end of 2022, indicating an increase of about 10%[14] - Accounts receivable increased significantly to RMB 673,484,506.18 from RMB 513,457,205.12, reflecting a growth of approximately 31%[14] - The company's cash and cash equivalents decreased to RMB 143,624,077.08 from RMB 197,133,665.75, a decline of about 27%[14] - Total liabilities rose to RMB 763,395,322.04 from RMB 726,796,211.73, marking an increase of around 5%[16] - The company's equity attributable to shareholders increased to RMB 1,704,854,607.71 from RMB 1,602,784,731.03, representing a growth of approximately 6%[16] - The company reported a decrease in inventory, which stood at RMB 170,605,554.76 compared to RMB 171,124,090.16 at the end of 2022, a slight decline of about 0.3%[14] - The company’s long-term equity investments slightly increased to RMB 10,162,761.58 from RMB 10,142,728.36, showing a marginal growth of about 0.2%[15] - The company’s short-term borrowings increased to RMB 289,170,242.99 from RMB 229,413,798.58, reflecting a rise of approximately 26%[15] - The company’s total non-current liabilities decreased to RMB 99,548,826.54 from RMB 109,753,887.96, indicating a reduction of about 9%[16] Cash Flow - The net cash flow from operating activities was -¥17,443,008.18, primarily due to reduced payments for experimental animals and increased tax refunds received[9] - Cash flow from operating activities showed a net outflow of RMB 17.4 million, an improvement from a net outflow of RMB 51.0 million in Q1 2022[23] - Cash and cash equivalents at the end of Q1 2023 were RMB 142.5 million, down from RMB 204.8 million at the end of Q1 2022[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,766[11] - The top shareholder, Chen Jinzhan, holds 15.64% of the shares, totaling 13,611,623 shares[11] Other Financial Metrics - The weighted average return on equity was 6.14%, an increase of 0.49 percentage points[6] - The company reported a tax expense of RMB 13.1 million for Q1 2023, compared to RMB 11.1 million in Q1 2022[20] - The company experienced a foreign exchange loss of RMB 770,934.14 in Q1 2023, compared to a loss of RMB 421,440.63 in Q1 2022[23]

会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 4 日(星期四)至 5 月 8 日(星期一)16:00 前登录上证路演 中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮箱 (IR@medicilon.com.cn)进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 证券代码：688202 证券简称：美迪西 公告编号：2023-025 上海美迪西生物医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 5 月 9 日(星期二)下午 13:00-14:30 上海美迪西生物医药股份有限公司（以下简称"公司"）于 2023 年 4 月 26 日在上海证券交易所网站（www.sse.com.cn）披露了公司 2022 ...